11 completed, 2 terminated, 2 unknown, 1 recruiting. 17 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 17 | Completed 11, Terminated 2, Unknown 2, Recruiting 1, Withdrawn 1 |
Follow nilotinib: new trials by email Literature Review of nilotinib trials Research Report on nilotinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Asciminib Roll-over Study Asciminib single agent, Imatinib, Nilotinib - Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive | Phase 4 | Recruiting | Novartis Pharmaceuticals | 347 | 2022-08-30 | 2026-11-09 |
| Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia Imatinib, Nilotinib - Chronyc Myeloid Leukemia | Phase 4 | Unknown | Gruppo Italiano Malattie EMatologiche dell'Adulto | 450 | 2016-11-11 | 2022-01-20 |
| Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline. Nilotinib - Chronic Myeloid Leukemia | Phase 4 | Completed | Novartis Pharmaceuticals | 171 | 2016-02-18 | 2022-07-22 |
| Multicenter, Phaseâ…£, Open Label Trial of Nilotinib in Adult Patients Diagnosed Philadelphia Chromosome Positive(Ph+) Chronic Myeloid Leukemia in CP/AP Intolerant to Dasatinib Nilotinib - Leukemia, Chronic Myeloid | Phase 4 | Unknown | Samsung Medical Center | 40 | 2015-04-01 | 2015-03-17 |
| Trial Evaluating Nilotinib as Treatment for Newly Diagnosed CML Patients in Accelerated Phase. AMN107 - Chronic Myeloid Leukemia (CML) | Phase 4 | Withdrawn | Novartis Pharmaceuticals | 2014-02-01 | 2017-04-20 | |
| Efficacy and Safety of Nilotinib in CML-CP Nilotinib - Chronic Myeloid Leukemia, Chronic Phase | Phase 4 | Completed | Seoul National University Hospital | 110 | 2013-05-06 | 2017-11-06 |
| Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study Nilotinib - Chronic Myelogenous Leukemia (CML), Metastatic Gastrointestinal Stromal Tumors (GIST) | Phase 4 | Completed | Novartis Pharmaceuticals | 57 | 2013-03-29 | 2024-02-08 |
| Efficacy and Safety Assessment of NIlotinib in CML Patients With Suboptimal Response on Imatinib Therapy Nilotinib 300 mg. - Myeloid Leukemia, Chronic | Phase 4 | Terminated | King Abdullah International Medical Research Center | 98 | 2013-03-01 | 2017-03-07 |
| CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib Nilotinib - Chronic Myelogenous Leukemia in Chronic Phase | Phase 4 | Completed | Novartis Pharmaceuticals | 128 | 2010-11-01 | 2016-02-08 |
| Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations nilotinib - CML, Philadelphia Chromosome Positive (Ph+) | Phase 4 | Terminated | Novartis Pharmaceuticals | 3 | 2010-10-21 | 2021-05-20 |
| Nilotinib in Newly Diagnosed Adult Philadelphia Chromosome & /or BCR-ABL Positive Chronic Myeloid Leukaemia in Chronic Phase Nilotinib - CML in Chronic Phase | Phase 4 | Completed | Novartis Pharmaceuticals | 1090 | 2010-05-01 | 2017-02-24 |
| Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response Nilotinib - Philadelphia Chromosome Positive, Chronic Myelogenous Leukemia in Chronic Phase | Phase 4 | Completed | Novartis Pharmaceuticals | 45 | 2009-12-01 | 2016-04-08 |
| An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment Nilotinib - Chronic Myelogenous Leukemia | Phase 4 | Completed | Novartis Pharmaceuticals | 52 | 2009-12-01 | 2021-07-01 |
| Tasigna in Glivec-resistant or Intolerant Patients in CML nilotinib - CML, Nilotinib | Phase 4 | Completed | Novartis Pharmaceuticals | 93 | 2009-02-01 | 2017-02-28 |
| Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to CAMN107A2109 Trial nilotinib - Chronic Myelogenous Leukemia | Phase 4 | Completed | Novartis Pharmaceuticals | 19 | 2008-12-01 | 2016-11-16 |
| Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib Nilotinib - Gastrointestinal Stromal Tumors | Phase 4 | Completed | Novartis Pharmaceuticals | 34 | 2008-08-29 | 2026-07-16 |
| Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Nilotinib - Chronic Myeloid Leukemia | Phase 4 | Completed | Novartis Pharmaceuticals | 89 | 2008-08-01 | 2017-02-23 |
Leukemia, Myelogenous, Chronic, BCR-ABL Positive (12) · Leukemia (4) · Blast Crisis (2) · Gastrointestinal Stromal Tumors (2) · Leukemia, Myeloid, Chronic-Phase (2) · Myeloproliferative Disorders (1) · Philadelphia Chromosome (1) · Piebaldism (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
Novartis Pharmaceuticals (13) · Gruppo Italiano Malattie EMatologiche dell'Adulto (1) · King Abdullah International Medical Research Center (1) · Samsung Medical Center (1) · Seoul National University Hospital (1)
Italy (5) · United States (5) · France (4) · Germany (4) · Spain (4) · Austria (3) · Brazil (3) · Canada (3) · Netherlands (3) · Poland (3) · South Korea (3) · United Kingdom (3) · Bulgaria (2) · Czechia (2) · Denmark (2)
Dr. Ahmad S. Alaskar, MD,FACP,FRCP (1) · Fabrizio Pane (1) · Inho Kim, MD (1)
PMID 26993758, PMID 27006491, PMID 27771544, PMID 28522574, PMID 29577674, PMID 30912699
2008 (1), 2009 (1), 2015 (1), 2023 (1)